[Federal Register Volume 90, Number 144 (Wednesday, July 30, 2025)]
[Notices]
[Pages 35877-35883]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-14411]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2025-N-2248]
Generic Drug User Fee Rates for Fiscal Year 2026
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Federal Food, Drug, and Cosmetic Act (FD&C Act or
statute), as amended by the Generic Drug User Fee Amendments of 2022
(GDUFA III), authorizes the Food and Drug Administration (FDA, Agency,
or we) to assess and collect fees for abbreviated new drug applications
(ANDAs); drug master files (DMFs); generic drug active pharmaceutical
ingredient (API) facilities, finished dosage form (FDF) facilities, and
contract manufacturing organization (CMO) facilities; and generic drug
applicant program user fees. In this document, FDA is announcing fiscal
year (FY) 2026 rates for GDUFA III fees.
DATES: These fees are effective on October 1, 2025, and will remain in
effect through September 30, 2026.
FOR FURTHER INFORMATION CONTACT: For more information on human generic
drug fees, visit FDA's website at: https://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments. For questions
relating to this notice: Olufunmilayo Ariyo, Office of Financial
Management, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20903, 240-402-4989; or the User Fees Support Staff
at [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Sections 744A and 744B of the FD&C Act (21 U.S.C. 379j-41 and 379j-
42), as amended by GDUFA III, authorize FDA to assess and collect fees
associated with human generic drug products. Fees are assessed on: (1)
certain types of applications for human generic drug products; (2)
certain facilities where APIs and FDFs are produced; (3) certain DMFs
associated with human generic drug products; and (4) generic drug
applicants who own one or more approved ANDAs (the program fee) (see
section 744B(a)(2) through (5) of the FD&C Act). For more information
about GDUFA III, please refer to the FDA website (https://www.fda.gov/gdufa).
For FY 2026, the generic drug user fee rates are ANDA ($358,247),
DMF ($102,584), domestic API facility ($43,549), foreign API facility
($58,549), domestic FDF facility ($238,943), foreign FDF facility
($253,943), domestic CMO facility ($57,346), foreign CMO facility
($72,346), large size operation generic drug applicant program
($1,918,377), medium size operation generic drug applicant program
($767,351), and small business generic drug applicant program
($191,838). These fees are effective on October 1, 2025, and will
remain in effect through September 30, 2026. The fee rates for FY 2026
are set out in table 1.
Table 1--Fee Schedule for FY 2026
------------------------------------------------------------------------
Fee rates for FY
Fee category 2026
------------------------------------------------------------------------
Applications:
Abbreviated New Drug Application (ANDA).......... $358,247
Drug Master File (DMF)........................... 102,584
Facilities:
Active Pharmaceutical Ingredient (API)--Domestic. 43,549
API--Foreign..................................... 58,549
Finished Dosage Form (FDF)--Domestic............. 238,943
FDF--Foreign..................................... 253,943
Contract Manufacturing Organization (CMO)-- 57,346
Domestic........................................
CMO--Foreign..................................... 72,346
GDUFA Program:
Large size operation generic drug applicant...... 1,918,377
Medium size operation generic drug applicant..... 767,351
Small business generic drug applicant............ 191,838
------------------------------------------------------------------------
II. Fee Revenue Amount for FY 2026
Under section 744B(b)(1)(B)(ii) of the FD&C Act, the base revenue
amount for FY 2026 for GDUFA III is $638,961,803. Under section
744B(c)(1) of the FD&C Act, applicable inflation adjustments to base
revenue shall be made beginning with FY 2024.
Under section 744B(c)(2) of the FD&C Act, for FY 2026, FDA shall,
in addition to the inflation adjustment, apply a capacity planning
adjustment to further adjust, as needed, the fee revenue and fees to
reflect changes in the resource capacity needs of FDA for human generic
drug activities.
Under section 744B(c)(3) of the FD&C Act, for FY 2026, FDA may, in
addition to the inflation and capacity planning adjustments, apply an
operating reserve adjustment to further increase the fee revenue and
fees if necessary to provide operating reserves of carryover user fees
for human generic drug activities for not more than the number of weeks
specified in such section (or as applicable, shall apply such
adjustment to decrease the fee revenues and fees to provide for not
more than 12 weeks of such operating reserves).
A. Inflation Adjustment
As noted above, the base revenue amount for FY 2026 is
$638,961,803. This is the total revenue amount specified for the prior
fiscal year, FY
[[Page 35878]]
2025, pursuant to the statute (see section 744B(b)(1)(A) of the FD&C
Act).\1\ GDUFA III specifies that the $638,961,803 is to be adjusted
for inflation for FY 2026 using two separate adjustments: one for
personnel compensation and benefits (PC&B) and one for non-PC&B costs
(see sections 744B(c)(1)(B) and (C) of the FD&C Act).
---------------------------------------------------------------------------
\1\ Under section 744B(b)(1)(B)(ii) of the FD&C Act, the base
revenue amount for a fiscal year is equal to the total revenue
amount established for the previous fiscal year, not including any
adjustments for such previous fiscal year under section 744B(c)(3).
---------------------------------------------------------------------------
The component of the inflation adjustment for PC&B costs shall be
the average annual percent change in the cost of all PC&B paid per
full-time equivalent (FTE) positions at FDA for the first 3 of the 4
preceding fiscal years, multiplied by the proportion of PC&B costs to
total FDA costs of human generic drug activities for the first 3 of the
preceding 4 fiscal years (see section 744B(c)(1)(B) of the FD&C Act).
Table 2 summarizes the actual cost and total FTEs for the specified
fiscal years and provides the percent change from the previous fiscal
year and the average percent change over the first 3 of the 4 fiscal
years preceding FY 2026. The 3-year average is 5.4494 percent.
Table 2--FDA Personnel Compensation and Benefits (PC&B) Each Year and Percent Change
----------------------------------------------------------------------------------------------------------------
Fiscal year 2022 2023 2024 3-Year average
----------------------------------------------------------------------------------------------------------------
Total PC&B.......................... $3,165,477,000 $3,436,513,000 $3,791,729,000 .................
Total FTEs.......................... 18,474 18,729 19,687 .................
PC&B per FTE........................ $171,348 $183,486 $192,601 .................
Percent Change from Previous Year... 4.2967% 7.0838% 4.9677% 5.4494%
----------------------------------------------------------------------------------------------------------------
The statute specifies that this 5.4494 percent should be multiplied
by the proportion of PC&B expended for human generic drug activities
for the first 3 of the preceding 4 fiscal years. Table 3 shows the
amount of PC&B and the total amount obligated for human generic drug
activities from FY 2022 through FY 2024.
Table 3--PC&B as a Percent of Fee Revenues Spent on Human Generic Drug Activities Over the Last 3 Years
----------------------------------------------------------------------------------------------------------------
Fiscal year 2022 2023 2024 3-Year average
----------------------------------------------------------------------------------------------------------------
PC&B................................ $391,922,747 $441,930,068 $479,495,256 .................
Non-PC&B............................ $289,479,265 $301,930,017 $278,861,828 .................
Total Costs......................... $681,402,012 $743,860,085 $758,357,084 .................
PC&B Percent........................ 57.5171% 59.4104% 63.2282% 60.0519%
Non-PC&B Percent.................... 42.4829% 40.5896% 36.7718% 39.9481%
----------------------------------------------------------------------------------------------------------------
The payroll adjustment is 5.4494 percent multiplied by 60.0519
percent (or 3.2725 percent).
The statute specifies that the portion of the inflation adjustment
for non-PC&B costs for FY 2026 is the average annual percent change
that occurred in the Consumer Price Index (CPI) for urban consumers
(Washington-Arlington-Alexandria Area, DC-VA-MD-WV; not seasonally
adjusted; all items; annual index) for the first 3 of the preceding 4
years of available data multiplied by the proportion of all costs other
than PC&B costs to total costs of human generic drug activities for the
first 3 years of the preceding 4 fiscal years (see section
744B(c)(1)(C) of the FD&C Act). Table 4 provides the summary data for
the percent change in the specified CPI.\2\
---------------------------------------------------------------------------
\2\ The data are published by the Bureau of Labor Statistics and
can be found on its website at: https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&series_id=CUURS35ASA0,CUUSS35ASA0.
Table 4--Annual and 3-Year Average Percent Change in CPI for Washington-Arlington-Alexandria Area
----------------------------------------------------------------------------------------------------------------
Year 2022 2023 2024 3-Year average
----------------------------------------------------------------------------------------------------------------
Annual CPI...................................... 296.117 305.317 315.186 ..............
Annual Percent Change........................... 6.6212% 3.1069% 3.2324% 4.3202%
----------------------------------------------------------------------------------------------------------------
To calculate the inflation adjustment for non-pay costs, we
multiply the 3-year average percent change in the CPI (4.3202 percent)
by the proportion of all costs other than PC&B to total costs of human
generic drug activities obligated. Because 60.0519 percent was
obligated for PC&B as shown in table 3, 39.9481 percent is the portion
of costs other than PC&B. The non-pay adjustment is 4.3202 percent
times 39.9481 percent, or 1.7258 percent.
To complete the inflation adjustment for FY 2026, we add the PC&B
component (3.2725 percent) to the non-PC&B component (1.7258 percent)
for a total inflation adjustment of 4.9983 percent (rounded), and then
add 1, making an inflation adjustment multiple of 1.049983. We then
multiply the base revenue amount for FY 2026 ($638,961,803) by
1.049983, yielding an inflation-adjusted amount of $670,899,031.
B. FY 2026 Statutory Fee Revenue Adjustments for Capacity Planning
The statute specifies that after the base revenue amount for FY
2026 of $638,961,803 has been adjusted for inflation as described in
section A above, the resulting amount shall be further adjusted to
reflect changes in the resource capacity needs for human generic drug
activities (see section 744B(c)(2) of the FD&C Act). Following a
process required in the statute, FDA
[[Page 35879]]
established the capacity planning adjustment (CPA) methodology that is
derived from the methodology and recommendations made in the report
titled ``Independent Evaluation of the GDUFA Resource Capacity Planning
Adjustment Methodology: Evaluation and Recommendations'' as announced
in the Federal Register of August 3, 2020, and incorporating approaches
and attributes determined appropriate by the Agency, except that the
workload drivers are limited to those specified in the GDUFA
Reauthorization Performance Goals and Program Enhancements Fiscal Years
2023-2027 (GDUFA III Commitment Letter).\3\ This methodology includes a
continuous, iterative improvement approach, under which the Agency
intends to refine its data and estimates for the core review activities
to improve the accuracy of its data and estimates over time.\4\
---------------------------------------------------------------------------
\3\ Section 744B(c)(2)(B) of the FD&C Act; see also section
VIII.B.2.e. of the GDUFA III Commitment Letter available at https://www.fda.gov/media/153631/download.
\4\ For example, FDA will aim to refine the CPA methodology to
reflect a more comprehensive assessment of the applicable workload
drivers across the Agency.
---------------------------------------------------------------------------
The CPA methodology consists of four steps:
1. Forecast workload volumes: predictive models estimate the volume
of workload for the upcoming FY.
2. Forecast the resource needs: forecast algorithms are generated
utilizing time reporting data. These algorithms estimate the required
demand in FTEs \5\ for direct review-related effort. This is then
compared to current available resources for the direct review-related
workload.
---------------------------------------------------------------------------
\5\ Full-time equivalents refer to a paid staff year, rather
than a count of individual employees.
---------------------------------------------------------------------------
3. A managerial adjustment to assess the resource forecast in the
context of additional internal factors: program leadership examines
operational, financial, and resourcing data to assess whether FDA will
be able to utilize additional funds during the fiscal year, and whether
the additional funds are required to support additional review
capacity. FTE amounts are adjusted, if needed.
4. Convert the FTE need to dollars: utilizing FDA's fully loaded
FTE cost model, the final feasible FTEs are converted to an equivalent
dollar amount.
Table 5 summarizes the forecasted workload volumes for the Center
for Drug Evaluation and Research (CDER) for FY 2026 based on predictive
models, as well as historical actuals from FY 2024 for comparison.
Table 5--CDER Actual FY 2024 Workload Volumes and Predicted FY 2026
Workload Volumes
------------------------------------------------------------------------
FY 2024 FY 2026
Workload driver category actuals predictions
------------------------------------------------------------------------
ANDA Originals \1\...................... 713 618
ANDA Supplements \2\.................... 11,807 11,699
Pre-ANDA Meetings....................... 95 91
Controlled Correspondences \3\.......... 3,277 3,092
Suitability Petitions................... 111 52
ANDA Annual Reports \4\................. 13,395 14,499
Active REMS Programs \4\ \5\............ 53 53
------------------------------------------------------------------------
\1\ Excludes response to refused to receive (RTR) and Orig-2+. ANDA
Original and Resubmissions/Amendments captured in time reporting data.
\2\ Includes changes being effected (CBE) and prior approval supplement
(PAS) Manufacturing and Labeling Supplements. PAS exclude response to
RTRs, risk evaluation and mitigation strategies (REMS) and
Bioequivalence Supplements. ANDA Supplement and Resubmissions/
Amendments captured in time reporting data.
\3\ Includes all requesting controlled correspondences.
\4\ Data represents workload related to resource needs for post-
marketing safety activities (developed in alignment with the
methodology used in fee-setting under PDUFA (section 736 of the FD&C
Act) (21 U.S.C. 379h) and BsUFA (section 744H of the FD&C Act) (21
U.S.C. 379j-52)), as applicable.
\5\ Represents the percentage of Active REMS Programs proportional to
Center and User Fee by total number of qualifying products with the
exclusion of the Opioid Shared System.
FDA anticipates that any FTE gains could be funded through the
expected FY 2026 collections amount without further adjustment from the
CPA. As such, FDA determined that in FY 2026 the GDUFA fee amounts do
not need adjustment from the CPA to provide funds for the program.
Table 6--Base Revenue Amount and Section 744B(c)(1) and (2) Adjustment
Amounts
------------------------------------------------------------------------
Fee Amount
------------------------------------------------------------------------
Statutory Fee Revenue Base Amount (section 744B(b)(1) $638,961,803
of the FD&C Act)....................................
Inflation Adjustment (section 744B(c)(1) of the FD&C 31,937,228
Act)................................................
Capacity Planning Adjustment (section 744B(c)(2) of 0
the FD&C Act).......................................
Revenue Amount after Adjustments in sections 670,899,031
744B(b)(1), 744B(c)(1), and 744B(c)(2) of the FD&C
Act.................................................
------------------------------------------------------------------------
C. FY 2026 Statutory Fee Revenue Adjustments for Operating Reserve
Under section 744B(c)(3) of the FD&C Act, for FY 2026, FDA may, in
addition to the inflation and capacity planning adjustments, apply an
operating reserve adjustment to further increase the fee revenue and
fees if necessary to provide operating reserves of carryover user fees
for human generic drug activities for not more than the number of weeks
specified in such section (or as applicable, shall apply such
adjustment to decrease the fee revenues and fees to provide for not
more than 12 weeks of such operating reserves).
The upward operating reserve adjustment is discretionary. For FY
2026, FDA may take an adjustment to provide for not more than 10 weeks
of operating reserve. If carryover is more than 12 weeks of operating
reserve, FDA
[[Page 35880]]
must decrease the fee revenues and fees to provide for not more than 12
weeks of operating reserve. To calculate the 10-week and 12-week
threshold amounts for the FY 2026 operating reserve adjustment, the FY
2026 adjusted revenue amount, $670,899,031 is divided by 52, resulting
in a $12,901,904 cost of operation for 1 week. The 1-week value is then
multiplied by 10 weeks to generate the 10-week operating reserve
threshold amount for FY 2026 of $129,019,040. The 1-week value is
multiplied by 12 to generate the 12-week operating reserve threshold
amount for FY 2026 of $154,822,848.
To determine the FY 2025 end-of-year operating reserves of
carryover user fees, the Agency assessed the operating reserve of
carryover user fees at the end of June 2025 and forecast collections
and obligations in the fourth quarter of FY 2025 combined. This
provides an estimated end-of-year FY 2025 operating reserve of
carryover user fees of $126,429,724 which equates to 9.80 weeks of
operations. As the estimated end-of-year FY 2025 operating reserve of
carryover user fees is just below the 10-week discretionary increase
threshold, there will not be an operating reserve adjustment.
Table 7 below summarizes FY 2026 fee revenue.
Table 7--Total Estimated Adjusted Revenue Amount
------------------------------------------------------------------------
Fee Amount
------------------------------------------------------------------------
Statutory Fee Revenue Base Amount (section 744B(b)(1) $638,961,803
of the FD&C Act)....................................
Inflation Adjustment (section 744B(c)(1) of the FD&C 31,937,228
Act)................................................
Capacity Planning Adjustment (section 744B(c)(2) of 0
the FD&C Act).......................................
Operating Reserve Adjustment (section (744B(c)(3) of 0
the FD&C Act).......................................
------------------
Total Revenue Amount (sections 744B(b)(1), 670,899,031
744B(c)(1), 744B(c)(2) and 744B(c)(3) of the
FD&C Act).......................................
------------------
Total Revenue Amount (rounded to the nearest 670,899,000
thousand dollars) (sections 744B(b)(1),
744B(c)(1), 744B(c)(2) and 744B(c)(3) of the
FD&C Act) (rounded to the nearest thousand).
------------------------------------------------------------------------
III. ANDA Filing Fee
Under GDUFA III, the FY 2026 ANDA filing fee is owed by each
applicant that submits an ANDA on or after October 1, 2025.\6\ This fee
is due on the submission date of the ANDA. Section 744B(b)(2)(B) of the
FD&C Act specifies that the ANDA fee will make up 33 percent of the
$670,899,000, which is $221,396,670.
---------------------------------------------------------------------------
\6\ Section 744B(a)(3) of the FD&C Act.
---------------------------------------------------------------------------
To calculate the ANDA fee, FDA estimated the number of full
application equivalents (FAEs) that will be submitted in FY 2026. The
submissions are broken down into three categories: new originals
(submissions that have not been received by FDA previously),
submissions that FDA RTR for reasons other than failure to pay fees,
and applications that are resubmitted after an RTR decision for reasons
other than failure to pay fees. An ANDA counts as one FAE; however, 75
percent of the fee paid for an ANDA that has been RTR shall be refunded
according to GDUFA III if: (1) the ANDA is refused for a cause other
than failure to pay fees or (2) the ANDA has been withdrawn prior to
receipt (section 744B(a)(3)(D)(i) of the FD&C Act). Therefore, an ANDA
that is considered not to have been received by FDA due to reasons
other than failure to pay fees or withdrawn prior to receipt counts as
one-fourth of an FAE. After an ANDA has been RTR, the applicant has the
option of resubmitting. For user fee purposes, these resubmissions are
equivalent to new original submissions: ANDA resubmissions are charged
the full amount for an application (one FAE).
As shown in table 5, FDA estimates that 618 new original ANDAs will
be submitted and incur filing fees in FY 2026. Not all the new original
ANDAs will be received by FDA and some of those not received will be
resubmitted in the same fiscal year. After accounting for these
factors, FDA expects that the FAE count for ANDAs will be 617.66,
rounded to 618 for FY 2026.
The FY 2026 ANDA filing fee is estimated by dividing the number of
FAEs that will incur the fee in FY 2026 (618) into the fee revenue
amount to be derived from ANDA filing fees in FY 2026 ($221,396,670).
The result, rounded to the nearest dollar, is a fee of $358,247 per
ANDA.
The statute provides that those ANDAs that include information
about the production of APIs other than by reference to a DMF will pay
an additional fee that is based on the number of such APIs and the
number of facilities proposed to produce those ingredients (see section
744B(a)(3)(F) of the FD&C Act). FDA anticipates that this additional
fee is unlikely to be assessed often; therefore, FDA has not included
projections concerning the amount of this fee in calculating the fees
for ANDAs.
IV. DMF Fee
Under GDUFA III, the DMF fee is owed by each person that owns a
type II API DMF that is referenced, on or after October 1, 2012, in a
generic drug submission by an initial letter of authorization.\7\ This
is a one-time fee for each DMF. This fee is due on the earlier of the
date on which the first generic drug submission is submitted that
references the associated DMF or the date on which the DMF holder
requests the initial completeness assessment. Under section
744B(a)(2)(D)(iii) of the FD&C Act, if a DMF has successfully undergone
an initial completeness assessment and the fee is paid, the DMF will be
placed on a publicly available list documenting DMFs available for
reference.
---------------------------------------------------------------------------
\7\ Section 744B(a)(2) of the FD&C Act.
---------------------------------------------------------------------------
To calculate the DMF fee, FDA assessed the volume of DMF
submissions over time. FDA assessed DMFs from October 1, 2022, to April
30, 2025, and concluded that averaging the number of fee-paying DMFs
provided the most accurate model for predicting fee-paying DMFs for FY
2026. The monthly average of paid DMF submissions FDA received from FY
2023 through April 2025 is 27.3. To determine the FY 2026 projected
number of fee-paying DMFs, the average of 27.3 DMF submissions is
multiplied by 12 months, which results in 327 estimated FY 2026 fee-
paying DMFs. FDA is estimating 327 fee-paying DMFs for FY 2026.
The FY 2026 DMF fee is determined by dividing the DMF target
revenue by the estimated number of fee-paying DMFs in FY 2026. Section
744B(b)(2)(A) of the FD&C Act specifies that the DMF fees will make up
5 percent of the $670,899,000, which is $33,544,950. Dividing the DMF
revenue amount
[[Page 35881]]
($33,544,950) by the estimated fee-paying DMFs (327), and rounding to
the nearest dollar, yields a DMF fee of $102,584 for FY 2026.
V. Foreign Facility Fee Differential
Under GDUFA III, the fee for a facility located outside the United
States and its territories and possessions shall be $15,000 higher than
the amount of the fee for a facility located in the United States and
its territories and possessions.\8\ The basis for this differential is
the extra cost incurred by conducting an inspection outside the United
States and its territories and possessions.
---------------------------------------------------------------------------
\8\ Section 744B(b)(2)(C) and (D) of the FD&C Act.
---------------------------------------------------------------------------
VI. FDF and CMO Facility Fees
Under GDUFA III, the annual FDF facility fee is owed by each person
who owns an FDF facility that is identified in at least one approved
generic drug submission owned by that person or its affiliates.\9\ The
CMO facility fee is owed by each person who owns an FDF facility that
is identified in at least one approved ANDA but is not identified in an
approved ANDA held by the owner of that facility or its affiliates.\10\
Section 744B(b)(2)(C) of the FD&C Act specifies that the FDF and CMO
facility fee revenue will make up 20 percent of the $670,899,000, which
is $134,179,800.
---------------------------------------------------------------------------
\9\ Section 744B(a)(4)(A) of the FD&C Act.
\10\ Section 744A(5) and 744B(b)(2)(C) of the FD&C Act.
---------------------------------------------------------------------------
To calculate the fees, data from FDA's Integrity Services (IS) were
utilized as the primary source of facility information for determining
the denominators of each facility fee type. IS is the master data
steward for all facility information provided in generic drug
submissions received by FDA. A facility's reference status in an
approved generic drug submission is extracted directly from submission
data rather than relying on data from self-identification. This
information provided the number of facilities referenced as FDF
manufacturers in at least one approved generic drug submission. These
findings were compared against facility statuses from FDA's Office of
Inspections and Investigations (OII) to exclude facilities that are no
longer operational.
Based on these data, the FDF and CMO facility denominators are 153
FDF domestic, 325 FDF foreign, 84 CMO domestic, and 142 CMO foreign
facilities for FY 2026.
GDUFA III specifies that the CMO facility fee is to be equal to 24
percent of the FDF facility fee.\11\ Therefore, to generate the target
collection revenue amount from FDF and CMO facility fees
($134,179,800), FDA must weight a CMO facility as 24 percent of an FDF
facility. FDA set fees based on the estimate of 153 FDF domestic, 325
FDF foreign, 20.16 CMO domestic (84 multiplied by 24 percent), and
34.08 CMO foreign facilities (142 multiplied by 24 percent), which
equals 532.24 total weighted FDF and CMO facilities for FY 2026.
---------------------------------------------------------------------------
\11\ Section 744B(b)(2)(C) of the FD&C Act.
---------------------------------------------------------------------------
To calculate the fee for domestic facilities, FDA first determines
the total fee revenue that will result from the foreign facility
differential by subtracting the fee revenue resulting from the foreign
facility fee differential from the target collection revenue amount
($134,179,800) as follows: the foreign facility fee differential
revenue equals the foreign facility fee differential ($15,000)
multiplied by the number of FDF foreign facilities (325) plus the
foreign facility fee differential ($15,000) multiplied by the number of
CMO foreign facilities (142), totaling $7,005,000. This results in
foreign fee differential revenue of $7,005,000 from the total FDF and
CMO facility fee target collection revenue.
Subtracting the foreign facility differential fee revenue
($7,005,000) from the total FDF and CMO facility target collection
revenue ($134,179,800) results in a remaining facility fee revenue
balance of $127,174,800. To determine the domestic FDF facility fee,
FDA divides the $127,174,800 by the total weighted number of FDF and
CMO facilities (532.24), which results in a domestic FDF facility fee
of $238,943. The foreign FDF facility fee is $15,000 more than the
domestic FDF facility fee, or $253,943.
According to GDUFA III, the domestic CMO fee is calculated as 24
percent of the amount of the domestic FDF facility fee.\12\ Therefore,
the domestic CMO fee is $57,346, rounded to the nearest dollar. The
foreign CMO fee is calculated as the domestic CMO fee plus the foreign
fee differential of $15,000. Therefore, the foreign CMO fee is $72,346.
---------------------------------------------------------------------------
\12\ Section 744B(b)(2)(C) of the FD&C Act.
---------------------------------------------------------------------------
VII. API Facility Fee
Under GDUFA III, the annual API facility fee is owed by each person
who owns a facility that is identified in at least one approved generic
drug submission in which the facility is approved to produce one or
more API or in a Type II API DMF referenced in at least one approved
generic drug submission.\13\ Section 744B(b)(2)(D) of the FD&C Act
specifies the API facility fee will make up 6 percent of $670,899,000
in fee revenue, which is $40,253,940.
---------------------------------------------------------------------------
\13\ Section 744B(a)(4)(A)(ii) of the FD&C Act.
---------------------------------------------------------------------------
To calculate the API facility fee, data from FDA's IS were utilized
as the primary source of facility information for determining the
denominator. As stated above, IS is the master data steward for all
facility information provided in generic drug submissions received by
FDA. A facility's reference status in an approved generic drug
submission is extracted directly from submission data rather than
relying on data from self-identification. This information provided the
number of facilities referenced as API manufacturers in at least one
approved generic drug submission. These findings were compared against
facility statuses from FDA's OII to exclude facilities that are no
longer operational.
Based on these data, the total number of API facilities identified
was 707; of that number, 76 were domestic and 631 were foreign
facilities. The foreign facility differential is $15,000. To calculate
the fee for domestic facilities, FDA must first subtract the fee
revenue that will result from the foreign facility fee differential.
FDA takes the foreign facility differential ($15,000) and multiplies it
by the number of foreign facilities (631) to determine the total fee
revenue that will result from the foreign facility differential. As a
result of this calculation, the foreign fee differential revenue will
make up $9,465,000 of the total API fee revenue. Subtracting the
foreign facility differential fee revenue ($9,465,000) from the total
API facility target revenue ($40,253,940) results in a remaining
balance of $30,788,940. To determine the domestic API facility fee, we
divide the $30,788,940 by the total number of facilities (707), which
gives us a domestic API facility fee of $43,549. The foreign API
facility fee is $15,000 more than the domestic API facility fee, or
$58,549.
VIII. Generic Drug Applicant Program Fee
Under GDUFA III, if a person and its affiliates own at least one
but not more than five approved ANDAs on October 1, 2025, the person
and its affiliates shall owe a small business generic drug applicant
program fee.\14\ If a person and its affiliates own at least 6 but not
more than 19 approved ANDAs, the person and its affiliates shall owe a
medium size operation generic drug applicant program fee.\15\ If a
person and its
[[Page 35882]]
affiliates own at least 20 approved ANDAs, the person and its
affiliates shall owe a large size operation generic drug applicant
program fee.\16\ Section 744B(b)(2)(E) of the FD&C Act specifies the
GDUFA program fee will make up 36 percent of $670,899,000 in fee
revenue, which is $241,523,640.
---------------------------------------------------------------------------
\14\ Sections 744B(a)(5)(A) and 744B(b)(2)(E)(i) of the FD&C
Act.
\15\ Id.
\16\ Id.
---------------------------------------------------------------------------
To determine the appropriate number of parent companies for each
tier, FDA asked companies to claim their ANDAs and affiliates in the
CDER NextGen Portal. The companies were able to confirm relationships
currently present in FDA's records, while also reporting newly approved
ANDAs, newly acquired ANDAs, and new affiliations.
In determining the appropriate number of approved ANDAs, FDA has
factored in a number of variables that could affect the collection of
the target revenue: (1) withdrawals of approved ANDAs by April 1:
applicants who have submitted a written request for withdrawal of
approval by April 1 of the previous fiscal year; \17\ (2) inactive
ANDAs: applicants who have not submitted an annual report for one or
more of their approved applications within the past 2 years; (3) CBER-
approved ANDAs: applicants and their affiliates with CBER-approved
ANDAs are added to CDER's population of approved ANDAs; (4) Program Fee
Arrears List: parent companies that are on the arrears list for any
fiscal year; (5) Out of Business companies: parent companies that are
no longer in operation; and (6) Tier Adjustment: the frequency of
large-tier, medium-tier, and small-tier companies moving to different
tiers (or as applicable, dropping out of any tier) after the completion
of the program fee methodology and tier determination.
---------------------------------------------------------------------------
\17\ See section 744B(b)(2)(E)(ii) of the FD&C Act.
---------------------------------------------------------------------------
The list of original approved ANDAs from the Generic Drug Review
Platform as of April 30, 2025, in addition to CBER's database, shows
259 applicants in the small business tier, 63 applicants in the medium
size tier, and 88 applicants in the large size tier. Factoring in all
the variables, we estimate there will be 221 applicants in the small
business tier, 57 applicants in the medium size tier, and 81 applicants
in the large size tier for FY 2026.
To calculate the GDUFA program fee, GDUFA III provides that large
size operation generic drug applicants pay the full fee, medium size
operation applicants pay two-fifths of the full fee, and small business
applicants pay one-tenth of the full fee.\18\ To generate the target
collection revenue amount from GDUFA program fees ($241,523,640), we
must weigh medium and small tiered applicants as a subset of a large
size operation generic drug applicant. FDA will set fees based on the
weighted estimate of 22.1 applicants in the small business tier (221
multiplied by 10 percent), 22.8 applicants in the medium size tier (57
multiplied by 40 percent), and 81 applicants in the large size tier,
arriving at 125.9 total weighted applicants for FY 2026.
---------------------------------------------------------------------------
\18\ Section 744B(b)(2)(E)(i) of the FD&C Act.
---------------------------------------------------------------------------
To generate the large size operation GDUFA program fee, FDA divides
the target revenue amount of $241,523,640 by 125.9, which equals
$1,918,377. The medium size operation GDUFA program fee is 40 percent
of the full fee ($767,351), and the small business GDUFA program fee is
10 percent of the full fee ($191,838).
IX. Fee Schedule for FY 2026
The fee rates for FY 2026 are displayed in table 8.
Table 8--Fee Schedule for FY 2026
------------------------------------------------------------------------
Fee rates for FY
Fee category 2026
------------------------------------------------------------------------
Applications:
Abbreviated New Drug Application (ANDA).......... $358,247
Drug Master File (DMF)........................... 102,584
Facilities:
Active Pharmaceutical Ingredient (API)--Domestic. 43,549
API--Foreign..................................... 58,549
Finished Dosage Form (FDF)--Domestic............. 238,943
FDF--Foreign..................................... 253,943
Contract Manufacturing Organization (CMO)-- 57,346
Domestic........................................
CMO--Foreign..................................... 72,346
GDUFA Program:
Large size operation generic drug applicant...... 1,918,377
Medium size operation generic drug applicant..... 767,351
Small business generic drug applicant............ 191,838
------------------------------------------------------------------------
X. Fee Payment Options and Procedures
The new fee rates are effective on October 1, 2025, and will remain
in effect through September 30, 2026. Under sections 744B(a)(4) and (5)
of the FD&C Act, respectively, facility and program fees are generally
due on the later of the first business day on or after October 1 of
each fiscal year or the first business day after the enactment of an
appropriations act providing for the collection and obligation of GDUFA
fees for the fiscal year.
To pay the ANDA, DMF, API facility, FDF facility, CMO facility, and
GDUFA program fees, complete the Generic Drug User Fee Cover Sheet,
available at https://www.fda.gov/gdufa and https://userfees.fda.gov/OA_HTML/gdufaCAcdLogin.jsp, and generate a user fee identification (ID)
number. Payment must be made in U.S. currency drawn on a U.S. bank by
electronic check, credit card, or wire transfer.\19\ The preferred
payment method is online using electronic check (Automated Clearing
House (ACH), also known as eCheck) or credit card (Discover, VISA,
MasterCard, American Express). FDA has partnered with the U.S.
Department of the Treasury to utilize Pay.gov, a web-based payment
application, for online electronic payment. The Pay.gov feature is
available on the FDA website after completing the Generic Drug User Fee
Cover Sheet and generating the user fee ID number.
---------------------------------------------------------------------------
\19\ See ``Change in Federal Payment and Collection Options''
announcement published in the Federal Register on June 27, 2025 (90
FR 27639).
---------------------------------------------------------------------------
Secure electronic payments can be submitted using the User Fees
Payment Portal at https://userfees.fda.gov/pay. (Note: Only full
payments are accepted;
[[Page 35883]]
no partial payments can be made online.) Once an invoice is located,
``Pay Now'' should be selected to be redirected to Pay.gov. Electronic
payment options are based on the balance due. Payment by credit card is
available for balances less than $25,000. If the balance exceeds this
amount, only the ACH option is available. Payments must be made using
U.S. bank accounts as well as U.S. credit cards.
For payments made by wire transfer, include the unique user fee ID
number to ensure that the payment is applied to the correct fee(s).
Without the unique user fee ID number, the payment may not be applied.
If the payment amount is not applied, the invoice amount will be
referred to collections. The originating financial institution may
charge a wire transfer fee. Include applicable wire transfer fees with
payment to ensure fees are fully paid. Questions about wire transfer
fees should be addressed to the financial institution. The following
account information should be used to send payments by wire transfer:
U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York,
NY 10045, account number: 75060099, routing number: 021030004, SWIFT:
FRNYUS33. FDA's tax identification number is 53-0196965.
Dated: July 25, 2025.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2025-14411 Filed 7-29-25; 8:45 am]
BILLING CODE 4164-01-P